Disease characteristics
| Characteristics . | N = 41 . |
|---|---|
| Baseline bone marrow blasts, median (range), % | 28 (2-77) |
| AML type (n = 40),∗ n (%) | |
| AML with myelodysplasia-related changes | 17 (42.5) |
| Acute myelomonocytic leukemia | 7 (17.5) |
| AML with RUNX-1 mutation | 5 (12.5) |
| AML with mutated NPM1 | 2 (5) |
| AML without maturation | 2 (5) |
| Pure erythroleukemia | 2 (5) |
| AML with maturation | 2 (5) |
| Other | 3 (7.5) |
| 2017 ELN risk category (n = 41), n (%) | |
| Adverse | 30 (73) |
| Intermediate | 7 (17) |
| Favorable | 4 (10) |
| Cytogenetics (n = 40),∗ n (%) | |
| Monosomy 7 or deletion 7 | 13 (32.5) |
| Complex karyotype | 10 (25) |
| Deletion 5 | 7 (17.5) |
| Molecular mutations (n = 36),∗ n (%) | |
| ASXL1 | 14 (39) |
| TP53 | 10 (24) |
| RUNX1 | 8 (22) |
| SRSF2 | 7 (19) |
| GATA2 | 5 (14) |
| STAG2 | 4 (11) |
| U2AF1 | 4 (11) |
| BCOR | 3 (8) |
| SF3B1 | 3 (8) |
| EXH2 | 3 (8) |
| Characteristics . | N = 41 . |
|---|---|
| Baseline bone marrow blasts, median (range), % | 28 (2-77) |
| AML type (n = 40),∗ n (%) | |
| AML with myelodysplasia-related changes | 17 (42.5) |
| Acute myelomonocytic leukemia | 7 (17.5) |
| AML with RUNX-1 mutation | 5 (12.5) |
| AML with mutated NPM1 | 2 (5) |
| AML without maturation | 2 (5) |
| Pure erythroleukemia | 2 (5) |
| AML with maturation | 2 (5) |
| Other | 3 (7.5) |
| 2017 ELN risk category (n = 41), n (%) | |
| Adverse | 30 (73) |
| Intermediate | 7 (17) |
| Favorable | 4 (10) |
| Cytogenetics (n = 40),∗ n (%) | |
| Monosomy 7 or deletion 7 | 13 (32.5) |
| Complex karyotype | 10 (25) |
| Deletion 5 | 7 (17.5) |
| Molecular mutations (n = 36),∗ n (%) | |
| ASXL1 | 14 (39) |
| TP53 | 10 (24) |
| RUNX1 | 8 (22) |
| SRSF2 | 7 (19) |
| GATA2 | 5 (14) |
| STAG2 | 4 (11) |
| U2AF1 | 4 (11) |
| BCOR | 3 (8) |
| SF3B1 | 3 (8) |
| EXH2 | 3 (8) |
ELN, European LeukemiaNet.
Results not available in some patients.